You are here » Home » Companies » Company Overview » Bal Pharma Ltd

Bal Pharma Ltd.

BSE: 524824 Sector: Health care
NSE: BALPHARMA ISIN Code: INE083D01012
BSE LIVE 15:26 | 09 Dec 99.70 -1.05
(-1.04%)
OPEN

101.40

HIGH

101.45

LOW

99.35

NSE LIVE 15:31 | 09 Dec 99.55 -1.55
(-1.53%)
OPEN

101.90

HIGH

101.95

LOW

99.30

OPEN 101.40
PREVIOUS CLOSE 100.75
VOLUME 13829
52-Week high 167.90
52-Week low 78.70
P/E 140.42
Mkt Cap.(Rs cr) 141.27
Buy Price 99.65
Buy Qty 70.00
Sell Price 100.10
Sell Qty 50.00
OPEN 101.40
CLOSE 100.75
VOLUME 13829
52-Week high 167.90
52-Week low 78.70
P/E 140.42
Mkt Cap.(Rs cr) 141.27
Buy Price 99.65
Buy Qty 70.00
Sell Price 100.10
Sell Qty 50.00

Bal Pharma Ltd. (BALPHARMA) - Company History

Bal Pharma (BPL), a member of the Mcro Laboratories group, was incorporated as a private limited company in May '87. In Mar.'90, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations. BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc. The company promotes its products through the common sales force of the group but proposes to induct its own soon. It came out with a public issue in Feb.'95 for manufacture of bulk drugs and expansion of pharmaceutical formulations. During 1997-98, the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July, 1997 the unit has become a division of Bal Pharma Limited. The company's product range has been expanded with the introduction of AZIWIN, CAFIMOL & CORTIDERM. The company has added further product range Zanovid, Aziwin, Dry Syrup, Meloxi, Ocium - M, Progit - MPS in its ethical division during 1999-2000. As part of the expansion of the product range, the company has introduced Cardiac Specialities Products. To market these products, a new division named "SERVETUS" has started functioning during 2001. New products like Amiloride,Benzydamine and Ebastine were rolled into the market during 2002.

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard